Ghent University Academic Bibliography

Advanced

Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study

JG Aerts, A Swieboda-Sadlej, C Karanikiotis, JL Labourey, A Galid, T Wheeler, B Pujol and Simon Van Belle UGent (2012) CURRENT MEDICAL RESEARCH AND OPINION. 28(7). p.1089-1099
abstract
Objectives: The CHOICE study was a prospective, multicentre, observational study designed to assess levels of adherence in current clinical practice to the European product label and EORTC guidelines for the treatment of chemotherapy-induced anaemia (CIA) with darbepoetin alfa (DA). Here we present data split by tumour types: breast, colorectal, ovarian and lung. Methods: Haemoglobin (Hb) levels and red blood cell transfusion requirements were evaluated among patients with solid tumours in 11 European countries. The primary outcome measure was the proportion of patients with a target Hb level of >= 10-<= 12 g/dL. Results: The full analysis set included 1887 patients (mean +/- SD 62.4 +/- 11.4 years); 1585 (84%) had a current disease stage of >= 3. Common chemotherapy regimens were non-platinum + non-taxane based (n = 696 [37%]) or platinum + non-taxane based (n = 660 [35%]). Breast cancer (n = 575): The mean +/- SD Hb level at baseline was 9.9 +/- 0.8 g/dL (n = 568). Target Hb level was reached by 187 (55%) patients. Colorectal cancer (n = 310): At baseline the mean +/- SD Hb level was 9.8 +/- 0.8 g/dL (n = 306). Target Hb level was reached by 107 patients (56%). Ovarian cancer (n = 301): The mean +/- SD Hb level at baseline was 9.7 +/- 0.8 g/dL (n = 294). Target Hb level was reached by 81 patients (44%). Lung cancer (n = 701): At baseline the mean +/- SD Hb level was 9.8 +/- 0.9 g/dL (n = 692). Target Hb level was reached by 142 patients (39%). Safety: Five severe or life-threatening adverse drug reactions were seen (three patients with breast cancer, one patient with colorectal cancer and one patient with ovarian cancer). Limitations: Potential bias could not be excluded due to the study's observational nature. Conclusions: This study demonstrates that the recommendations are adhered to in clinical practice, with the mean starting Hb level <10 g/dL irrespective of tumour type. Furthermore, DA is likely to be effective and well tolerated for the treatment of CIA in patients with breast, colorectal, ovarian or lung cancer.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
Chemotherapy-induced anaemia (CIA), Colorectal cancer, Breast cancer, Darbepoetin alfa (DA), European summary of product characteristics (SPC), Haemoglobin (Hb), Lung cancer, Ovarian cancer, Red blood cell (RBC) transfusion, Routine clinical, ERYTHROPOIESIS-STIMULATING AGENTS, CANCER-ASSOCIATED ANEMIA, HEMOGLOBIN LEVELS, DOUBLE-BLIND, GYNECOLOGIC CANCER, EORTC GUIDELINES, LUNG, BREAST, SAFETY, METAANALYSIS
journal title
CURRENT MEDICAL RESEARCH AND OPINION
Curr. Med. Res. Opin.
volume
28
issue
7
pages
1089 - 1099
Web of Science type
Article
Web of Science id
000306130800002
JCR category
MEDICINE, GENERAL & INTERNAL
JCR impact factor
2.263 (2012)
JCR rank
35/149 (2012)
JCR quartile
1 (2012)
ISSN
0300-7995
DOI
10.1185/03007995.2012.698602
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2974236
handle
http://hdl.handle.net/1854/LU-2974236
date created
2012-08-23 10:09:48
date last changed
2012-10-11 11:19:43
@article{2974236,
  abstract     = {Objectives: The CHOICE study was a prospective, multicentre, observational study designed to assess levels of adherence in current clinical practice to the European product label and EORTC guidelines for the treatment of chemotherapy-induced anaemia (CIA) with darbepoetin alfa (DA). Here we present data split by tumour types: breast, colorectal, ovarian and lung. 
Methods: Haemoglobin (Hb) levels and red blood cell transfusion requirements were evaluated among patients with solid tumours in 11 European countries. The primary outcome measure was the proportion of patients with a target Hb level of {\textrangle}= 10-{\textlangle}= 12 g/dL. 
Results: The full analysis set included 1887 patients (mean +/- SD 62.4 +/- 11.4 years); 1585 (84\%) had a current disease stage of {\textrangle}= 3. Common chemotherapy regimens were non-platinum + non-taxane based (n = 696 [37\%]) or platinum + non-taxane based (n = 660 [35\%]). 
Breast cancer (n = 575): The mean +/- SD Hb level at baseline was 9.9 +/- 0.8 g/dL (n = 568). Target Hb level was reached by 187 (55\%) patients. 
Colorectal cancer (n = 310): At baseline the mean +/- SD Hb level was 9.8 +/- 0.8 g/dL (n = 306). Target Hb level was reached by 107 patients (56\%). 
Ovarian cancer (n = 301): The mean +/- SD Hb level at baseline was 9.7 +/- 0.8 g/dL (n = 294). Target Hb level was reached by 81 patients (44\%). 
Lung cancer (n = 701): At baseline the mean +/- SD Hb level was 9.8 +/- 0.9 g/dL (n = 692). Target Hb level was reached by 142 patients (39\%). 
Safety: Five severe or life-threatening adverse drug reactions were seen (three patients with breast cancer, one patient with colorectal cancer and one patient with ovarian cancer). 
Limitations: Potential bias could not be excluded due to the study's observational nature. 
Conclusions: This study demonstrates that the recommendations are adhered to in clinical practice, with the mean starting Hb level {\textlangle}10 g/dL irrespective of tumour type. Furthermore, DA is likely to be effective and well tolerated for the treatment of CIA in patients with breast, colorectal, ovarian or lung cancer.},
  author       = {Aerts, JG and Swieboda-Sadlej, A and Karanikiotis, C and Labourey, JL and Galid, A and Wheeler, T and Pujol, B and Van Belle, Simon},
  issn         = {0300-7995},
  journal      = {CURRENT MEDICAL RESEARCH AND OPINION},
  keyword      = {Chemotherapy-induced anaemia (CIA),Colorectal cancer,Breast cancer,Darbepoetin alfa (DA),European summary of product characteristics (SPC),Haemoglobin (Hb),Lung cancer,Ovarian cancer,Red blood cell (RBC) transfusion,Routine clinical,ERYTHROPOIESIS-STIMULATING AGENTS,CANCER-ASSOCIATED ANEMIA,HEMOGLOBIN LEVELS,DOUBLE-BLIND,GYNECOLOGIC CANCER,EORTC GUIDELINES,LUNG,BREAST,SAFETY,METAANALYSIS},
  language     = {eng},
  number       = {7},
  pages        = {1089--1099},
  title        = {Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study},
  url          = {http://dx.doi.org/10.1185/03007995.2012.698602},
  volume       = {28},
  year         = {2012},
}

Chicago
Aerts, JG, A Swieboda-Sadlej, C Karanikiotis, JL Labourey, A Galid, T Wheeler, B Pujol, and Simon Van Belle. 2012. “Use of Darbepoetin Alfa in European Clinical Practice for the Management of Chemotherapy-induced Anaemia in Four Tumour Types: Final Data from the CHOICE Study.” Current Medical Research and Opinion 28 (7): 1089–1099.
APA
Aerts, JG, Swieboda-Sadlej, A., Karanikiotis, C., Labourey, J., Galid, A., Wheeler, T., Pujol, B., et al. (2012). Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study. CURRENT MEDICAL RESEARCH AND OPINION, 28(7), 1089–1099.
Vancouver
1.
Aerts J, Swieboda-Sadlej A, Karanikiotis C, Labourey J, Galid A, Wheeler T, et al. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study. CURRENT MEDICAL RESEARCH AND OPINION. 2012;28(7):1089–99.
MLA
Aerts, JG, A Swieboda-Sadlej, C Karanikiotis, et al. “Use of Darbepoetin Alfa in European Clinical Practice for the Management of Chemotherapy-induced Anaemia in Four Tumour Types: Final Data from the CHOICE Study.” CURRENT MEDICAL RESEARCH AND OPINION 28.7 (2012): 1089–1099. Print.